RU2017122796A - Композиции и способы, включающие триглицериды со средней длиной цепи, для лечения эпилепсии - Google Patents

Композиции и способы, включающие триглицериды со средней длиной цепи, для лечения эпилепсии Download PDF

Info

Publication number
RU2017122796A
RU2017122796A RU2017122796A RU2017122796A RU2017122796A RU 2017122796 A RU2017122796 A RU 2017122796A RU 2017122796 A RU2017122796 A RU 2017122796A RU 2017122796 A RU2017122796 A RU 2017122796A RU 2017122796 A RU2017122796 A RU 2017122796A
Authority
RU
Russia
Prior art keywords
animal
aed
food composition
tsc
acid
Prior art date
Application number
RU2017122796A
Other languages
English (en)
Other versions
RU2017122796A3 (ru
RU2712942C2 (ru
Inventor
Юанлонг ПАН
Брайан Майкл ЗАНГХИ
Жан-Кристоф БУТГУР
Original Assignee
Нестек Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нестек Са filed Critical Нестек Са
Publication of RU2017122796A publication Critical patent/RU2017122796A/ru
Publication of RU2017122796A3 publication Critical patent/RU2017122796A3/ru
Application granted granted Critical
Publication of RU2712942C2 publication Critical patent/RU2712942C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A23K20/147—Polymeric derivatives, e.g. peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/20—Inorganic substances, e.g. oligoelements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A23K50/42—Dry feed
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A23K50/45—Semi-moist feed
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Birds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pediatric Medicine (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fodder In General (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (22)

1. Режим питания, пригодный для усиления эффекта противоэпилептического средства (AED) у животного, включающий AED и пищевую композицию, содержащую триглицерид со средней длиной цепи (ТСЦ), где ТСЦ присутствует в пищевой композиции в эффективном количестве для усиления эффекта AED при введении животному пищевой композиции и AED.
2. Режим питания по п. 1, где животное представляет собой человека или животное-компаньона.
3. Режим питания по п. 1, где животное представляет собой животное из семейства псовых или кошачьих.
4. Режим питания по п. 1, в котором ТСЦ имеет следующую формулу (формула 1):
Figure 00000001
,
где каждый R’, R’’ и R’’’, этерифицированный с цепью глицерина, представляет собой независимую жирную кислоту с 5–12 атомами углерода.
5. Режим питания по п. 5, где более чем около 95% из R’, R’’ и R’’’ имеют цепь из 8 атомов углерода.
6. Режим питания по п. 6, где остальные R’, R’’ и R’’’ являются 6-углеродными или 10-углеродными жирными кислотами.
7. Режим питания по п. 1, где пищевая композиция содержит от около 1% до около 15% ТСЦ.
8. Режим питания по п. 1, где AED выбирают из группы, состоящей из ацетазоламида, карбамазепина, хлоразепата, клобазама, клоназепама, диазепама, ацетата эсликарбазепина, этисиксунудема, этосуксимида, фелбамата, габапентина, имепитоина, кеппры, лакозамида, ламотригина, леветирацетама, метилфенобарбитона, нитразепама, окскарбазепина, перампанела, пирацетама, фенобарбитала, фенитоина, бромида калия, прегабалина, примидона, ретигабина, руфинамида, бромида натрия, вальпроата натрия, стирипентола, сультиама, тиагабина, топирамата, вальпроевой кислоты, вигабатрина, зонисамида, их солей, их производных и их смесей.
9. Режим питания по п. 1, где пищевая композиция составлена в виде пищевой композиции для человека, композиции корма для домашних животных или диетической добавки.
10. Режим питания по п. 1, где пищевая композиция дополнительно содержит от около 15% до около 50% белка, от около 5% до около 40% жира, от около 5% до около 10% содержания золы и имеет влагосодержание от около 5% до около 20%.
11. Режим питания по п. 1, где пищевая композиция включает AED.
12. Способ усиления эффекта противоэпилептического средства (AED) у животного, включающий введение животному пищевой композиции, содержащей триглицерид со средней длиной цепи (ТСЦ), в сочетании с противоэпилептическим средством (AED), причем для усиления эффекта AED у животного ТСЦ вводят в эффективном количестве.
13. Способ по п. 12, где животное представляет собой человека или животное-компаньона.
14. Способ по п. 12, где животное представляет собой животное из семейства псовых или кошачьих.
15. Способ по п. 12, где ТСЦ имеет формулу 1, где каждый R’, R’’ и R’’’, этерифицированный с цепью глицерина, представляет собой независимую жирную кислоту с 5–12 атомами углерода, а AED выбирают из группы, состоящей из ацетазоламида, карбамазепина, хлоразепата, клобазама, клоназепама, диазепама, ацетата эсликарбазепина, этисиксунудема, этосуксимида, фелбамата, габапентина, имепитоина, кеппры, лакозамида, ламотригина, леветирацетама, метилфенобарбитона, нитразепама, окскарбазепина, перампанела, пирацетама, фенобарбитала, фенитоина, бромида калия, прегабалина, примидона, ретигабина, руфинамида, бромида натрия, вальпроата натрия, стирипентола, сультиама, тиагабина, топирамата, вальпроевой кислоты, вигабатрина, зонисамида, их солей, их производных и их смесей.
16. Способ по п. 12, где пищевая композиция содержит от около 1% до около 15% ТСЦ, и пищевую композицию вводят одновременно с AED.
17. Способ по п. 12, где пищевую композицию вводят на длительной регулярной основе.
18. Способ по п. 12, где пищевую композицию вводят животному ежедневно.
19. Способ по п. 12, где введение приводит к уменьшению частоты судорожных припадков у животного на по меньшей мере 50% по сравнению с введением AED вместе с пищевой композицией, не содержащей ТСЦ.
20. Фармацевтическая композиция для усиления эффекта противоэпилептического средства (AED) у животного, содержащая триглицерид со средней длиной цепи (ТСЦ) и AED, где ТСЦ присутствует в эффективном количестве для усиления эффекта AED при введении животному фармацевтической композиции.
RU2017122796A 2014-12-08 2015-12-07 Композиции и способы, включающие триглицериды со средней длиной цепи, для лечения эпилепсии RU2712942C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462088797P 2014-12-08 2014-12-08
US62/088,797 2014-12-08
PCT/IB2015/059417 WO2016092459A1 (en) 2014-12-08 2015-12-07 Compositions and methods comprising medium chain triglycerides for treatment of epilepsy

Publications (3)

Publication Number Publication Date
RU2017122796A true RU2017122796A (ru) 2019-01-10
RU2017122796A3 RU2017122796A3 (ru) 2019-04-05
RU2712942C2 RU2712942C2 (ru) 2020-02-03

Family

ID=54979885

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017122796A RU2712942C2 (ru) 2014-12-08 2015-12-07 Композиции и способы, включающие триглицериды со средней длиной цепи, для лечения эпилепсии

Country Status (18)

Country Link
US (1) US9789079B2 (ru)
EP (1) EP3229790B1 (ru)
JP (1) JP6923440B2 (ru)
CN (1) CN106998748A (ru)
AU (1) AU2015358958B2 (ru)
CA (1) CA2968666C (ru)
CL (1) CL2017001472A1 (ru)
DK (1) DK3229790T3 (ru)
ES (1) ES2761826T3 (ru)
HR (1) HRP20192023T1 (ru)
LT (1) LT3229790T (ru)
MX (1) MX2017007230A (ru)
NZ (1) NZ730880A (ru)
PL (1) PL3229790T3 (ru)
PT (1) PT3229790T (ru)
RU (1) RU2712942C2 (ru)
SI (1) SI3229790T1 (ru)
WO (1) WO2016092459A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2944260A1 (en) * 2014-04-08 2015-10-15 Specialites Pet Food Method for selecting petfoods having a palatability effect and a calorie intake reducing effect for pets
EP3149686A2 (en) * 2014-05-26 2017-04-05 Spécialités Pet Food Methods for selecting a petfood providing a satisfying feeding experience upon consumption by pets
JP7030194B2 (ja) 2017-11-17 2022-03-04 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド オメガ－３ポリ不飽和および中鎖脂肪酸を含む組成物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2319508A1 (en) 2000-05-01 2011-05-11 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
NZ544009A (en) * 2003-07-24 2009-07-31 Euro Celtique Sa Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain
AU2005258021B2 (en) 2004-06-17 2008-12-18 Wisconsin Alumni Research Foundation Compounds and methods for treating seizure and paroxysmal disorders
WO2006105019A1 (en) 2005-03-25 2006-10-05 Wisconsin Alumni Research Foundation Compounds and methods for treating seizure disorders
JP2009508855A (ja) * 2005-09-16 2009-03-05 ディーエスエム アイピー アセッツ ビー．ブイ． 医薬品用微粒子状脂質組成物
HUE035852T2 (en) 2006-04-03 2018-05-28 Accera Inc Use of ketogen compounds to treat memory decline
WO2009005519A1 (en) * 2007-06-29 2009-01-08 Accera, Inc. Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism
MX2010003568A (es) * 2007-10-04 2010-04-21 Nestec Sa Composiciones y metodos para mejorar la funcion cognitiva.
EP2303036A1 (en) 2008-07-03 2011-04-06 Accera, Inc. Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
WO2014027023A1 (en) * 2012-08-14 2014-02-20 Nestec S.A. Dietetic compositions for the treatment of malnutrition, neurological diseases and metabolic diseases
RU2018132041A (ru) 2012-08-21 2018-11-13 Сейдж Терапьютикс, Инк. Способы лечения эпилепсии или эпилептического статуса

Also Published As

Publication number Publication date
PL3229790T3 (pl) 2020-04-30
AU2015358958A1 (en) 2017-04-27
CL2017001472A1 (es) 2018-01-05
RU2017122796A3 (ru) 2019-04-05
PT3229790T (pt) 2020-01-22
CA2968666A1 (en) 2016-06-16
HRP20192023T1 (hr) 2020-02-07
NZ730880A (en) 2022-07-01
LT3229790T (lt) 2019-12-10
AU2015358958B2 (en) 2020-10-01
MX2017007230A (es) 2017-10-16
WO2016092459A1 (en) 2016-06-16
JP2018504368A (ja) 2018-02-15
BR112017010381A2 (pt) 2017-12-19
EP3229790B1 (en) 2019-10-16
EP3229790A1 (en) 2017-10-18
US9789079B2 (en) 2017-10-17
JP6923440B2 (ja) 2021-08-18
SI3229790T1 (sl) 2020-02-28
RU2712942C2 (ru) 2020-02-03
CN106998748A (zh) 2017-08-01
DK3229790T3 (da) 2019-12-16
ES2761826T3 (es) 2020-05-21
US20160158183A1 (en) 2016-06-09
CA2968666C (en) 2022-08-30

Similar Documents

Publication Publication Date Title
Pal et al. A review on role of fish in human nutrition with special emphasis to essential fatty acid
Givens et al. Current intakes of EPA and DHA in European populations and the potential of animal-derived foods to increase them: Symposium on ‘How can the n-3 content of the diet be improved?’
Fernandes et al. Nutritional and lipid profiles in marine fish species from Brazil
Tur et al. Dietary sources of omega 3 fatty acids: public health risks and benefits
RU2012132294A (ru) Композиции, содержащие имбирь, для облегчения или предотвращения воспалительных состояний
CA2660291C (en) Methods of improving bone health and muscle health
Li et al. Bone mineral content is positively correlated to n-3 fatty acids in the femur of growing rats
Turchini et al. Transforming salmonid aquaculture from a consumer to a producer of long chain omega-3 fatty acids
RU2009135260A (ru) Композиции и способы изменения экспрессии генов
RU2013146517A (ru) Композиции и способы, пригодные для облегчения возрастных заболеваний
Monteschio et al. The effect of encapsulated active principles (eugenol, thymol and vanillin) and clove and rosemary essential oils on the structure, collagen content, chemical composition and fatty acid profile of Nellore heifers muscle
Oluwaniyi et al. Effect of cooking method on the proximate, amino acid and fatty acid compositions of Clarias gariepinus and Oreochromis niloticus
RU2017122796A (ru) Композиции и способы, включающие триглицериды со средней длиной цепи, для лечения эпилепсии
Malcorps et al. Nutritional characterisation of European aquaculture processing by-products to facilitate strategic utilisation
JP2014515011A5 (ru)
RU2015154968A (ru) Композиции для проглатывания, содержащие компонент авокадо криойо
KR20190049686A (ko) 오메가-3 다중불포화 지방산 조성물을 포함하는 동물 사료
Vilain et al. Nutritional and health value of fish: the case of Cambodia
Daidj et al. Hepatoprotective and anti-obesity properties of sardine by-product oil in rats fed a high-fat diet
JP6538043B2 (ja) 腎機能を向上させるための方法及び組成物
Lima et al. The cutting by-product of fish filleting on the band saw machine: Nutritional quality and technological potential
Immanuel et al. Processing and characterisation of low cost Balistid fish Sufflamen capistratus liver oil for edible purpose
Tengku-Rozaina et al. Nutritional composition and thermal properties Of goldstripe sardinella (Sardinella gibbosa) fillets and by-products
Pickova Importance of knowledge on lipid composition of foods to support development towards consumption of higher levels of n-3 fatty acids via freshwater fish.
Balshaw et al. Risk-benefit analysis of fish consumption: Fatty acid and mercury composition of farmed southern bluefin tuna, Thunnus maccoyii

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant